Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
The association of Crohn's disease and ankylosing spondylitis is described in up to 30% of cases. Treatment of both conditions is not an easy task. We present the case of a 53 year old woman, diagnosed with colonic Crohn's disease and ankylosing spondilitis, treated initially with increasing doses of sulphasalazine and moderate dose of corticosteroids, with the persistence of severe gastrointestinal and articular symptoms. She underwent therapy with tumor necrosis factor alpha (TNFalpha) inhibitor infliximab, with a spectacular improvement of symptoms, signs and quality of life.
Rednic
Simona
S
Department of Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania. srednic@umfcluj.ro
Marinescu
Claudiu
C
Chira
Romeo
R
Rogojan
Liliana
L
Rednic
Nicolae
N
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001706:Biopsy; D003106:Colon / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D003113:Colonoscopy; D003424:Crohn Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy*; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome; D014463:Ultrasonography
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D012460:Sulfasalazine; D000069285:Infliximab